## SEC Form 4

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

5. Relationship of Reporting Person(s) to Issuer

Check this box if no longer subject to	STATEN
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name **and** Ticker or Trading Symbol

					2. Issuer Name and Ticker or Trading Symbol       5. Relationship of Reporting Person(s) to Issuer (Check all applicable)         SOLENO THERAPEUTICS INC       [ SLNO ]         Director       X         10% Owner										Dwner				
I (Last) (First) (Middle)					e of Earliest /2017	Tran	saction (I	Month	n/Day/Year)		Officer (give title Other (specify below) below)								
(Street) PALO ALTO CA 94301					<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>Form filed by One Reporting Person</li> <li>X</li> <li>Form filed by More than One Reporting Person</li> </ul>														
(City)	(5	State)	(Zip)																
			ble I - N						· 	d, Di	sposed o								
1. Title of Security (Instr. 3) Date (Month/Day/Year)				Execution Date,		3. Transaction Code (Instr. 8) Code V		4. Securities Acqui Disposed Of (D) (In Amount (A)		(Instr. 3	A) or , 4 and 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common	Stock			12/1	5/201	7			Р		1,072,88	+	D) A	(Instr. 3 and 4)				I	See footnote <sup>(1)</sup>
Common	Stock				5/201				Р		12,592		A	\$1.8425	425 45,667			Ι	See footnote <sup>(2)</sup>
			Table II								posed of converti				Dwned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transa Code ( 8)			ve es d (A) sed str.	6. Date Expirati (Month/	ion Da			ecuritie erlying vative S	s Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng d	10. Ownersh Form: Direct (D) or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	n or Nu		Amount or Number of Shares		(Instr. 4)			
Common Stock Warrant (Right to Buy)	\$2	12/15/2017			Р		793,937		12/15/2	2017	(3)		imon ock	793,937	(4)	793,9	937	I	See footnote <sup>(1)</sup>
Common Stock Warrant (Right to Buy)	\$2	12/15/2017			Р		9,318		12/15/2017		(3)	Common Stock		9,318	(5)	9,318		I	See footnote <sup>(2)</sup>
		f Reporting Person*	т				1						,			*		*	
<u></u>	entures V	<u>, LLC</u>																	
(Last) 505 HAI	MILTON A	(First) VENUE, SUITE	-	idle)															
(Street) PALO A	LTO	СА	943	801															
(City)		(State)	(Zip	)															
		f Reporting Person <sup>*</sup> 7 Affiliates Fu		<u>.</u>															
(Last) 505 HAI	MILTON A	(First) VENUE, SUITE	-	ldle)															
(Street) PALO A	LTO	СА	943	801															
(City)		(State)	(Zip	)															

1. Name and Address of Reporting Person\*

<u>Vivo Ventures</u>	<u>Fund V, L.P.</u>							
(Last)	(First)	(Middle)						
505 HAMILTON AVENUE, SUITE 207								
(Street)								
PALO ALTO	CA	94301						
(Citra)	(Stata)	(7in)						
(City)	(State)	(Zip)						

#### Explanation of Responses:

1. The securities are held directly by Vivo Ventures Fund V. L.P. ("Vivo Ventures Fund V"). The Reporting Person is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein.

2. The securities are held directly by Vivo Ventures V Affiliates Fund L.P. ("Vivo Ventures V Affiliates Fund"). The Reporting Person is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures V Affiliates Fund. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein.

3. The warrant has a term of three years and, in the event of positive Phase III results for Diazoxide Choline Controlled-Release (DCCR) tablet in Prader-Willi syndrome (PWS), the warrant will expire 30 days from the announcement of such results.

4. The reported securities are included within 1,072,888 units purchased by the Reporting Person for \$1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.

5. The reported securities are included within 12,592 units purchased by the Reporting Person for \$1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.

**Remarks:** 

### <u>/s/ Frank Kung, Managing</u> Member

<u>12/19/2017</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.